The Schall Law Firm is investigating Oculis Holding AG for potentially misleading investors after the company announced its Phase 3 DIAMOND drug trials failed to meet primary endpoints. Oculis had previously claimed the trials were progressing as planned but later revealed it would not seek FDA approval based on the trial results. Investors who suffered losses are encouraged to join the class action lawsuit. This case highlights risks in biotech investments when clinical trial outcomes are unfavorable and disclosures may be delayed or inaccurate.
Mavenir was awarded Deutsche Telekom's Partner of the Year for its Most Energy Efficient Core (MeeC) project, which reduces 5G core network energy use by up to 65% during low traffic periods without compromising performance. The project, launched in ...
Mavenir received Deutsche Telekom's Partner of the Year award for network innovation, recognizing its key role in the MeeC project that reduced 5G core network energy consumption by up to 65% during low traffic periods. The MeeC initiative uses AI-dr...
Mavenir received Deutsche Telekom's Partner of the Year Award for Best Network Innovation, recognizing its role in the MeeC project that cut 5G core network energy use by up to 65%. The project uses AI-driven traffic analysis and workload optimizatio...
Mavenir received Deutsche Telekom's Partner of the Year Award for Best Network Innovation due to its MeeC project, which achieved up to 65% energy savings in Deutsche Telekom's 5G core network without compromising performance. The MeeC initiative use...
Mavenir received Deutsche Telekom's Partner of the Year award for Best Network Innovation, recognizing its role in the Most Energy Efficient Core (MeeC) project. MeeC, launched in 2025, uses AI-driven traffic analysis and workload optimization to red...
